P
PTC Therapeutics, Inc. (PTCT)
NMS – Real vaqt narxi. Valyuta: USD
75.02
-1.83 (-2.38%)
Yopilishda: May 12, 2026, 4:00 PM EDT
75.52
+0.50 (0.67%)
Bozor oldidan: May 13, 2026, 8:11 AM EDT
Aksiya tahlili uchun eng kuchli vositalarga ega bo'ling
Find any stock by ticker or company name
NMS – Real vaqt narxi. Valyuta: USD
75.02
-1.83 (-2.38%)
Yopilishda: May 12, 2026, 4:00 PM EDT
75.52
+0.50 (0.67%)
Bozor oldidan: May 13, 2026, 8:11 AM EDT
PTC Therapeutics, Inc., biofarmatsevtika kompaniyasi, Qo'shma Shtatlar va xalqaro miqyosda kam uchraydigan kasalliklar bilan yashayotgan bolalar va kattalar uchun dori vositalarini kashf qilish, ishlab chiqish va tijoratlashtirishga qaratilgan. Kompaniya Duchenne mushak distrofiyasini davolash uchun Translarna va Emflaza; markaziy asab tizimi kasalligi bo'lgan aromatik L-amino kislotasi dekarboksilaza (AADC) etishmovchiligini davolash uchun Upstaza; kam uchraydigan kasalliklarni davolash uchun Tegsedi va Waylivra; hamda kattalar va bolalarda spinal mushak atrofiyasini (SMA) davolash uchun Evrysdi'ni taqdim etadi. Kompaniyaning ishlab chiqish jarayonidagi mahsulotlari orasida fenilketonuriyani davolash uchun Sepiapterin; Xantington kasalligini davolash uchun ishlab chiqilayotgan PTC518 splicing platformasi; va Friedreich ataksiyasini davolash uchun vatiquinoneni o'z ichiga olgan yallig'lanish va ferroptoz platformalari mavjud. Kompaniya o'z mahsulotlarini uchinchi tomon distribyutorlari orqali tarqatadi. U F. Hoffman-La Roche Ltd., Hoffman-La Roche Inc., SMA Foundation, Tayvan Milliy Universiteti, Akcea Therapeutics, Inc. va Shiratori Pharmaceutical Co., Ltd. bilan hamkorlik qiladi. Kompaniya Xantington kasalligi bo'yicha PTC518 dasturini ishlab chiqish uchun Novartis Pharmaceuticals Corporation bilan litsenziya va hamkorlik shartnomasiga ega. Kompaniya AQShda Kebilidi savdo belgisi ostida gen terapiyasi bo'lgan Upstaza'ni sotadi. PTC Therapeutics, Inc. 1998 yilda tashkil etilgan va shtab-kvartirasi Uorren, Nyu-Jersi shahrida joylashgan.
| Ism | Lavozim |
|---|---|
| Dr. Allan Steven Jacobson Ph.D. | Co-Founder & Independent Director |
| Dr. Lee Scott Golden M.D., Ph.D. | Executive VP & Chief Medical Officer |
| Dr. Matthew B. Klein F.A.C.S., M.D., M.S. | CEO & Director |
| Dr. Neil Almstead Ph.D. | Chief Technical Operations Officer |
| Mr. Eric Pauwels | Chief Business Officer |
| Mr. Mark Elliott Boulding J.D. | Executive VP & Chief Legal Officer |
| Sana | Turi | Hujjat |
|---|---|---|
| 2026-05-07 | 10-Q | tmb-20260331x10q.htm |
| 2026-04-28 | 8-K | tmb-20260428x8k.htm |
| 2026-04-20 | DEFA14A | tmb-20260420xdefa14a.htm |
| 2026-03-25 | 8-K | tmb-20260324x8k.htm |
| 2026-02-19 | 8-K | tmb-20260219x8k.htm |
| 2026-02-19 | 10-K | tmb-20251231x10k.htm |
| 2026-02-12 | 8-K | tmb-20260212x8k.htm |
| 2026-01-12 | 8-K | tmb-20260112x8k.htm |
| 2025-12-29 | 8-K | tmb-20251229x8k.htm |
| 2025-11-04 | 10-Q | tmb-20250930x10q.htm |
| Mr. Pierre Gravier M.S. | Chief Financial Officer |
| Ms. Christine Utter CPA | Senior VP, Chief Accounting Officer & Head of People Services |
| Ms. Ellen Cavaleri | Head of Investor Relations |
| Ms. Linda Montella Carter | Senior VP & Chief Information Officer |